Comorbidity in risk and outcome of hematological malignancies by Mohammadi, Mohammad
From THE INSTITUTE OF ENVIRONMENTAL MEDICINE 
Karolinska Institutet, Stockholm, Sweden 
COMORBIDITY IN RISK AND OUTCOME 
OF 
 HEMATOLOGICAL MALIGNANCIES 
Mohammad Mohammadi 
 
Stockholm 2016 
 
 All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Printed by Universitetsservice US-AB 
© Mohammad Mohammadi, 2016 
ISBN 978-91-7676-247-9 
Comorbidity in risk and outcome of 
hematological malignancies  
THESIS FOR DOCTORAL DEGREE (Ph.D.) 
 
 
ACADEMIC DISSERTATION 
This thesis will be defended in public at seminar rum Petrén, Nobels väg 12b 
Karolinska Institutet, Solna 
At 9:00 on Wednesday, March 23rd, 2016 
By 
Mohammad Mohammadi 
 
Principal Supervisor: 
Karin Ekström Smedby 
Karolinska Institutet 
Department of Medicine 
Unit of Clinical Epidemiology 
 
Co-supervisor(s): 
Yang Cao 
Karolinska Institutet 
Institute of Environmental Medicine 
Division of Epidemiology 
 
Matteo Bottai 
Karolinska Institutet 
Institute of Environmental Medicine 
Division of Epidemiology 
Opponent: 
Herman Nilsson-Ehle 
Göteborg University 
Department of Internal Medicine 
Division of Hematology 
 
Examination Board: 
Marie Reilly 
Karolinska Institutet 
Department of Medical Epidemiology and 
Biostatistics 
 
Jan Adolfsson 
Karolinska Institutet 
Department of Clinical Science, Intervention and 
Technology 
 
Martin Erlanson 
Umeå University 
Department of Radiation Sciences 
 
 
 
 
 
 
 
 
  
To memory of my father 
To my mother 
To Elham, Saba and Sina 
 
  
  
  
ABSTRACT 
Hematological malignancies are a group of neoplasms that originate from the bone marrow or 
lymphatic tissues representing close to 10% of the overall cancer burden in the world. 
Clinical course, prognosis and survival varies greatly from very aggressive disease requiring 
intensive systemic chemotherapy-based treatment to indolent forms without need of therapy 
at diagnosis. Patients are typically diagnosed at old age and may have other comorbid 
diseases that have to be taken into account for optimal treatment and care. Comorbid diseases 
may constitute risk factors for the development of subtypes of hematological malignancies, 
and/or determinants of complications and death.  The aim of this thesis was to evaluate the 
association and impact of comorbid diseases on mortality in leukemia, myeloma and 
lymphoma, risk of suicidal behavior and death following diagnoses of hematological 
malignancies, especially considering mental comorbidity, and finally evaluating 
appendectomy as a potential risk factor for hematological malignancy of lymphoid origin. 
The study cohorts of the four papers in this thesis were created by linkage between Swedish 
national health care registers (studies I-III) and the national Swedish quality register for 
lymphoma (study IV).  
In study I, we evaluated risk of attempted and completed suicide in a cohort of 46,309 
patients diagnosed with lymphoma, myeloma or leukemia in Sweden 1992-2009 compared 
with a set of cancer-free individuals using Poisson regression. The relative risk of completed 
suicide was 3.5-fold increased among patients with myeloma and 1.9-fold increased among 
patients with lymphoma but not significantly increased among patients with leukemia. Risk 
of attempted suicide was also increased among patients with myeloma and lymphoma. 
History of mental disorders conferred highly increased risks. 
Next (study II), we evaluated the association and impact of comorbidity in general and 
specific comorbid diseases (defined according to the Charlson index) on all-cause and cancer-
specific mortality in patients with acute myeloid leukemia (AML), chronic myeloid leukemia 
(CML) or myeloma, accounting for competing risks in analyses of cancer-specific death. 
Comorbidity was associated with increased all-cause as well as cancer-specific mortality. 
Disorders associated with higher cancer-specific mortality were renal disease (in AML, 
CML, myeloma), cerebrovascular conditions, dementia, psychiatric disease (AML, 
myeloma), liver and rheumatic disease (AML), cardiovascular and pulmonary disease 
(myeloma).  
In study III, we evaluated the association between comorbid disease history and lymphoma 
characteristics, treatment selection and lymphoma-specific mortality among patients with 
diffuse large B-cell lymphoma (DLBCL), an aggressive lymphoma subtype. Comorbid 
patients had a significantly higher relative probability of presenting with low performance 
status compared with patients without comorbidity, and a lower relative probability of 
receiving curative treatment, leading to increased risks of all-cause as well as lymphoma-
specific death. Among patients selected for curative treatment, comorbid disease was 
associated with all-cause but not lymphoma-specific death.  
Finally, in study IV, in light of mixed results in previous studies, we examined risk of 
lymphoid neoplasms in a cohort of 337,437 appendectomized patients <60 years of age in 
Sweden 1975-2009. We did not observe any clear associations between appendectomy and 
risk of non-Hodgkin lymphoma overall or major subtypes, myeloma or acute lymphoblastic 
leukemia.  An increased risk of Hodgkin lymphoma was noted among patients diagnosed 
with appendicitis and for the nodular sclerosis subtype of HL, which could reflect a true 
association, or shared susceptibility to infection/inflammation among individuals prone to 
develop HL. 
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1 INTRODUCTION 
Hematological malignancies represent a heterogeneous group of neoplasms with regard to 
etiology and molecular biology as well as treatment, clinical course and survival and 
therefore constitute a large challenge for patients, their families, and the physicians 
(oncologists/hematologists) caring for them. Together, they represent close to 10% of 
incident cancers worldwide [1]. From a public health viewpoint, in Sweden in 2002, total 
costs of, e.g. acute myeloid leukemia (AML), one of the most aggressive forms of 
hematological malignancies, was estimated to generate direct costs of 225 million SEK and 
indirect costs of 236 million SEK [2].  
Several known/suggested risk factors for hematological malignancies have been presented 
but most cases remain unexplained. A range of disorders affecting the lymphatic system and 
immune response, including most notably HIV/AIDS, organ transplantations, but also less 
severe states of immune perturbation such as autoimmune and chronic inflammatory 
conditions and infections, constitute risk factors for several subtypes of hematological 
malignancies. Other risk factors include smoking and ionizing radiation. The appendix is rich 
in lymphatic tissue and appendectomy and its common cause, appendicitis, has been 
suggested as a possible risk for hematological malignancies of lymphoid origin in some 
studies [3-7].  
Whereas some specific comorbid disorders are clearly of etiologic relevance in hematologic 
malignancies and may alter biology and clinical course, many other common comorbidities 
still constitute important factors that can affect treatment selection, prognosis and survival [8-
16]. The incidence of most subtypes of hematological malignancies increases with age, as is 
the case with many chronic diseases as well as other cancer forms. However, as opposed to 
solid cancer where successful primary treatment is often based on radical surgical excision, 
treatment in hematological malignancies typically rely on prolonged chemotherapy-based 
treatment schedules with toxic effects on vital organs including the kidney, liver, heart and 
lungs. Worse outcomes among cancer patients with comorbidities, and perhaps especially 
among patients with hematological malignancies, can therefore be expected, nevertheless 
needs to be managed as optimally as possible. Cancer patients are also known to be at 
increased risk of suicide. Suicide is an avoidable cause of death that is believed to complicate 
cancer because of high level of distress after a cancer diagnosis in itself, but may also be 
related to uncontrolled pain and other physical symptoms and the prognosis of the cancer 
diagnosed [17-25]. Few previous studies have addressed potential variation in risk of suicide 
among patients with different subtypes of hematological malignancies. 
In this thesis, we evaluated risk of suicide in patients with hematological malignancy 
subtypes, associations and impact of comorbid disease histories with mortality in leukemia 
and myeloma, associations with lymphoma characteristics, treatment intent and mortality in 
diffuse large B-cell lymphoma, and lastly the potential association between appendectomy 
and risk of hematological malignancies of lymphoid origin.
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2 BACKGROUND 
Hematological malignancies originate from myeloid or lymphoid cells residing in the bone 
marrow or lymphatic tissues. Major malignancy types in this group primarily include acute 
lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia 
(CML), and malignant lymphomas. According to the most recent and widely adopted WHO 
classification system the group of lymphomas includes a number of sub entities, for example 
chronic lymphocytic leukemia (CLL) and multiple myeloma, although according to the 
International Classification of diseases (ICD), these last entities are coded as separate 
disorders.  
Studies to date suggest that environmental factors may play a larger role in the etiology of 
leukemia and lymphoma than genetic factors, although family history and low penetrance 
genetic traits are of importance as well [26-33]. However, for most newly diagnosed cases, 
the etiology is elusive, and therefore, efforts to identify potential etiologies remain an active 
research area. 
Cure is often a realistic goal of treatment for leukemia and lymphoma, especially in younger 
patients. Survival has increased in recent years across all age categories partly through the use 
of new treatment protocols, including immunological and more recently also biological 
therapies [34].  
2.1 LEUKEMIA 
Leukemia is a malignant transformation of white blood cells to leukemic cells. Leukemic 
cells replace normal bone marrow cells and consequently decrease/suppress hematopoiesis 
and patients therefore often present with anemia, thrombocytopenia and granulocytopenia. 
Organomegaly such as hepatomegaly, splenomegaly and lymphadenopathy are also common. 
Leukemias are divided into acute forms characterized by immature poorly differentiated cells, 
and chronic forms characterized by more mature cells. Myelodysplastic syndromes are 
disorders of bone marrow transformation where the blast count is less than a definite 
diagnosis of AML.   
The incidence of leukemia overall varies between racial and ethnic groups with different 
genetic make-ups. Incidence rates are highest in the United States, Australia, and Germany 
and intermediate in most European countries [35]. In Europe 2012, the highest incidence was 
reported in Cyprus (15.9/100,000 for men and 9.7/100,000 for women) and the lowest in 
Bosnia Herzegovina (4.3/100.000 for men and 3.3/100,000 for women) [36].  
Chemical agents such as benzene and formaldehyde, air pollution [37-41], smoking [42-44] 
and obesity [45] have been demonstrated to increase risk of leukemia.  
2.1.1 Acute lymphoblastic leukemia (ALL)  
Acute lymphoblastic leukemia is the most common malignancy in childhood, and about half 
of the cases occur in childhood and teenagers, and half in adults. The age-adjusted overall 
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incidence rate of ALL in the United States is 1.5 per 100 000 [46, 47]. In 2014, incidence 
rates were 1.4 for males and 1.2 for females per 100,000 in Sweden [48]. Individuals with 
Down’s syndrome are at increased risk [49].   
5-year survival (2005-2011) reported from the USA was 70.1% [50]. Treatment of ALL 
includes several chemotherapy phases. The first step is remission induction aiming to 
eliminate the bulk- leukemia cell population. Remission induction may be repeated if the 
patient is not in remission. The next phase is consolidation therapy [51], and the last step is 
maintenance therapy. 
2.1.2 Acute myeloid leukemia (AML) 
The incidence of AML increases with age [2], and the median age at diagnosis is around 69 
years [52]. It is more common among males than among females [52]. In 2014, the incidence 
rate was 3.1 for males and 2.6 for females per 100,000 in Sweden [48]. Environmental risk 
factors include ionizing radiation, magnetic fields and cigarette smoking [53-61]. Risks are 
also increased following post organ transplant immune suppression [62]. The molecular 
heterogeneity of AML is increasingly recognized. The current WHO classification recognizes 
four major categories (AML with recurrent genetic abnormalities, AML with 
myelodysplasia-related changes, therapy-related AML and AML not otherwise specified), but 
a revision is under way.  
Treatment primarily includes intensive induction chemotherapy, and post-remission 
consolidative therapy with conventional chemotherapy or hematopoietic-cell transplantation 
[63]. Outcome depends on the pathobiology of AML and genetic abnormalities, age, 
performance status and comorbid diseases. Patients older than 60-70 years may not be 
eligible for intensive treatment. By age group, 24% of 75-84 year-olds and 6% of patients 
older than 85 years received intensive treatment in Sweden, and otherwise, the patients 
received a less toxic dose of chemotherapy [64, 65]. 5-year survival (2005-2011) reported 
from USA was 26.0%. 
2.1.3 Chronic myeloid leukemia (CML) 
Median age at diagnosis of CML is approximately 60 years. CML is uncommon, and in 2014, 
incidence rates were 1.3 for males and 0.9 for females per 100,000 in Sweden [48]. Risk 
factors for CML include ionizing radiation [66], and organ transplantation [62]. 
Survival of patients with CML has improved dramatically after the introduction of tyrosine 
kinase inhibitors in the beginning of the 21st century. Imatinib as the first member of tyrosine 
kinase family replaced cytoreductive therapies and interferon used as traditional treatments 
for CML [67, 68]. In Sweden, 5-year survival in the period of 2002-2010 was 81% and for 
patients diagnosed in a chronic phase the 5-year survival was 83% [69].  
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2.2 LYMPHOMA 
Lymphoma is a malignancy of the lymphatic system. Malignant lymphomas constitute the 
most common hematological malignancies in adults. Traditionally, there are two main 
categories of lymphomas, the non-Hodgkin lymphomas (NHL, 90%), and Hodgkin 
lymphoma (HL, 10%). NHL represent clonal expansions of B-, T- or NK cells, of which B-
cell NHLs are by far the most common. The hallmark of HL tumors is the presence of the 
Reed-Sternberg cells, recently shown to be of B-cell origin.  
The Ann Arbor staging system is used to classify disease spread and provides a basis for 
prognostic evaluation and treatment selection for both HL and NHL patients [70, 71]. 
According to Ann Arbor, lymphomas are classified into 4 stages based on localization of 
malignancy. Primary extranodal NHL are classified according to the Musshoff system. 
Table 1. Ann Arbor staging system 
Ann Arbor Staging system 
Stage  
I Involvement of a single lymph node region 
II 
Involvement of two or more lymph node regions on the same side of the 
diaphragm 
III Involvement of lymph node regions on both sides of the diaphragm 
IV Diffuse or disseminated extra nodal involvement 
2.2.1  Hodgkin lymphoma (HL) 
The highest incidence rates are found in Yemen and Lebanon at >5.5 per 100,000. The 
incidence rate in Sweden is 2.1 per 100,000 for males and 1.7 per 100,000 for females [72]. 
Previous studies showed that patients with HIV/AIDS [73], delayed infection with Epstein-
Barr virus (mononucleosis) [74] and smokers [75, 76] are at increased risk of HL. Genetic 
variation in the human leukocyte antigen (HLA) region is also associated with HL risk [77]. 
HL is highly sensitive to chemotherapy and radiotherapy. The main cause of death in patients 
is the adverse effect of treatment such as cardiovascular and secondary cancer [78-80]. 5-year 
survival (2005-2011) reported from USA was 88.3%. 
2.2.2 Non-Hodgkin lymphoma (NHL)  
NHL are a group of heterogeneous malignancies arising from lymphocytes residing in lymph 
nodes, bone marrow or in any organ of the body. Diffuse large B-cell lymphoma and 
follicular lymphoma are the most common subtypes of NHL, but they can be further 
subdivided into more than 40 groups according to WHO classification (2008). Clinically, 
NHL is subdivided into indolent and aggressive forms. The indolent types progress slowly 
and are seldom possibly to cure. The aggressive types progress fast but response well to 
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treatment in most instances. Follicular lymphomas represent a common indolent group 
whereas diffuse large B-cell lymphomas (DLBCL) are aggressive. 
The highest incidence rates of NHL are observed in Northern America (16.9 per 100,000), 
Australia and New Zealand (14.3 per 100,000) and Western Europe (11 per 100,000). The 
incidence rate in Sweden is 14.7 per 100,000 for males and 10.3 per 100,000 for females [72]. 
Risk factors include family history, strong immune suppression (HIV/AIDS, organ 
transplantation, rare inherited immunodeficiency syndromes) but also disorders of immune 
activation [81]. Treatment of NHL is based on combination chemotherapy, immunotherapy 
(most notably anti-CD20 antibodies) and radiotherapy. 5-year survival (2005-2011) reported 
from USA was 71.9%.  
2.2.2.1 Diffuse large B-cell lymphoma (DLBCL) 
DLBCL is the most common subtype of NHL [82]. The 5-year survival in Sweden has been 
reported to range from 74 percent among patients younger than 40 years to 22 percent among 
patients older than 79 years [82]. The disease is aggressive and requires rapid initiation of 
intensive treatment. The standard treatment for DLBCL is 14 or 21 day cycle of rituximab 
with, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP-14 or R-CHOP-
21) [83]. For prophylaxis against central nervous system recurrence, intrathecal methotrexate 
and cytarabine and intravenous methotrexate has been recommended [83]. Positron emission 
tomography (PET) scan is used with increasing frequency for evaluation of treatment 
response. 
The International Prognostic Index (IPI) has been developed to predict prognosis and guide 
treatment decisions in DLBCL [84]. Accordingly, age older than 60, Ann Arbor Stage III or 
IV, elevated serum-lactate dehydrogenase (LD), performance status 2, 3 or 4 and having 
more than one extra nodal disease location are considered as risk factors [84]. Recently, a 
refined IPI (NCCN-IPI) was suggested based on patients treated during the rituximab-era, 
proposing further refinement by age and by certain major extranodal locations including the 
central nervous system (CNS), bone marrow, lung and the gastrointestinal tract including 
liver [85].    
2.2.2.2 Follicular lymphoma 
Follicular lymphoma is the most common indolent subtype of NHL. Asymptomatic patients 
are managed with a watch-and-wait policy. For symptomatic patients, Rituximab as 
monotherapy or in combination with chemotherapy is the first line treatment in Sweden [86]. 
In Sweden, 5-year and 10-year survival for patients aged <60 years in the period 2003-2010 
were 91% and 83%, respectively [86]. 
2.2.2.3 Small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL, hereafter 
only denoted CLL) 
CLL is a disease involving lymphocytes in the bone marrow, lymph nodes and other organs, 
and is mostly of B-cell type. Lymphocytosis in the blood distinguishes CLL from SLL. CLL 
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affects males twice as frequently as females [87]. In 2008, the incidence rate was 6.5 for male 
and 3.1 for female per 100000 in Sweden [48]. Family history is a clear risk factor for CLL 
[33, 88, 89]. CLL does not need to be treated if asymptomatic. If blood counts decrease and 
symptoms occur, treatment includes chemotherapy, immunotherapy and/or radiotherapy. The 
5-year survival (2005-2011) in the USA was 84.8%.  
2.3 MYELOMA  
Multiple myeloma and the localized form plasmocytoma, is a malignancy of the plasma cell, 
an antigen-producing B cell. Transformed plasma cells accumulate in the bone marrow and 
cause several clinical characteristics of myeloma such as anemia and bone pain. 
Accumulation of paraproteins may lead to amyloidosis and/or renal failure. Asymptomatic 
myeloma is routinely not treated. Patients with symptomatic myeloma require chemotherapy 
and/or immunomodulatory therapy. Intensive treatment with hematopoietic-cell 
transplantation are options for younger patients.  
Multiple myeloma is the second most prevalent hematological malignancy after NHL. It is 
more common in men than women. In the USA the incidence is 7.1 per 100 000 in men and 
4.6 per 100 000 in women. [90]. In Sweden, age standardized incidence rate is 7.7 per 
100,000 for men and 5.1 per 100,000 for women [48]. In previous studies, hair coloring [91], 
pesticides [92], obesity [92], pernicious anemia and ankylosing spondylitis [92, 93] and 
family history [94] have been suggested as risk factors for myeloma. 5-year survival (2005-
2011) reported from USA was 48.5%. 
2.4 SUICIDE 
Suicide is the third cause of death among young adults (ages 15-44 years) leading to one 
million avoidable deaths worldwide every year [95]. Completed suicide may be preceded by 
one or several suicide attempts. The rate of attempted suicide is higher than completed 
suicide [96]. Age, gender and ethnicity influence suicide rates [97-99], and a range of 
additional predictors of suicidal behavior have also been described in the literature including 
psychiatric disorders and substance abuse, severe somatic disorder, uncontrolled pain, chronic 
or bad prognosis disease such as cancer, lack of social support, unemployment, and 
socioeconomic factors such as migration [100-106]. Higher suicide rates shortly after 
diagnosis of cancer including hematological malignancies have been reported in several 
studies [1, 17-23, 107, 108]. However, few previous studies considered risks by subtypes of 
hematological malignancies. Given the large differences in levels of treatment and care 
among patients with hematological malignancies, subtype-specific risks are needed to inform 
health care personnel caring for these patients. 
2.5 COMORBIDITY 
Disorders involving the heart, lungs, liver or kidneys represent an additional challenge to the 
treating physicians since cancer patients with such comorbidities can be expected to have a 
lower tolerance to standard chemotherapy-based regimens. Therefore, a common clinical 
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problem at diagnosis of adult and elderly patients is to evaluate comorbid disease history in 
relation to treatment channeling, prognosis and survival.  
Severe comorbid disease increases overall mortality in cancer patients [109-113] including 
patients with hematological malignancies [8-12, 114]. However, among patients with 
hematological malignancies, there is a focus on studies of patients eligible for hematopoietic 
stem cell transplantation [14-16, 115], excluding many elderly patients. Fewer studies have 
addressed if comorbidities also increase risks of cancer-specific mortality. A Danish study 
reported that severe comorbidity increases overall but not cancer-specific mortality among 
colorectal and prostate cancer patients but increases both overall and cancer-specific 
mortality in lung cancer cases [109, 110]. Among patients with AML, history of comorbid 
disease is associated with overall survival and with complete remission rates [10-12]. In some 
but not all studies, a worse survival was noted among NHL and DLBCL patients with a high 
comorbidity index as measured with different scales [118-120]. A recent study found that 
rheumatoid arthritis improved prognosis in NHL [116]. In contrast another cohort study from 
Sweden reported decreased survival times in NHL [117].  
Comorbid diseases may affect overall and cancer-specific survival through biological 
mechanisms if they are related to disease etiology, as is the case, e.g. in HIV/AIDS and organ 
transplantation leading to increased risks specifically of EBV-driven aggressive NHL [81]. 
However, and more importantly in terms of patient numbers, comorbidity in general may 
affect treatment tolerability and choice of treatment intensity as well as modality. In 
investigations of associations and impact of comorbidity in general on cancer outcomes, 
choices have to be made about the scope and measurement of comorbid diseases. To this end, 
researchers have presented several models to define and measure comorbid diseases.  
Charlson Comorbidity Index (CCI): In 1987, Charlson et al. developed a model for 
estimating effects of comorbid disease on mortality in non-cancer patients, revised later by 
other researchers for use based on administrative data [118, 119]. Charlson classified the 
comorbid diseases in 19 groups and assigned a score from 1 to 6 to each disease in order to 
capture the number and severity of the diseases [118]. This index has become widely used.  
Elixhauser comorbidity model: In 1998, Elixhauser presented a comorbidity adjustment 
model including 30 comorbid diseases. Elixhauser expanded the comorbidity list with, e.g., 
mental disorders, drug and alcohol abuse, coagulopathies, and fluid and electrolyte disorders 
[120]. 
The Adult Comorbidity Evaluation 27 index (ACE27): The ACE27 includes 27 comorbid 
diseases and a grading of severity into 3 grades: mild, moderate and severe [121]. 
Hematopoietic cell transplantation (HCT)-specific comorbidity index (HCT-CI): This is a 
modified version of CCI for predicting the prognosis in candidates for hematopoietic-cell 
transplantation [122]. 
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2.6 APPENDECTOMY 
Appendix is a part of the secondary lymphoid tissues and a place for presenting food-, drug- 
and microorganism-antigens to the blood and lymphoid system [123]. Appendectomy is still 
one of the most common surgical procedures around the world [124] and potential long term 
consequences of this procedure are therefore important to investigate. Given its role in the 
immune system, removal of the appendix may have immunological consequences, and some 
studies reported immunoglobulin changes after appendectomy [125, 126].  
In 1964, MacWay observed an increased risk of cancer after appendectomy in an autopsy 
study [127]. He then hypothesized a protective role of appendix against carcinogen viruses 
[3]. However, some negative studies followed [128, 129]. With regard to hematological 
malignancies, Hyams reported a higher prevalence of HL, and later, Cope et al. reported an 
increased risk of NHL among patients younger than 20 years, following appendectomy [4, 6]. 
However, yet other studies have reported no increase in risks of hematological malignancies 
after appendectomy [5, 130-132]. Appendectomy and/or appendicitis could potentially be 
associated with risk of hematological malignancies through immune dysfunction [133-135], 
inflammation and infection [6, 136, 137] and/or other effects related to the gut microbiome  
[138, 139]. 
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3 AIMS OF THE THESIS  
3.1 GENERAL AIM 
The overall aim of the thesis was to increase knowledge of the association between 
comorbidities and outcome in hematological malignancies, including suicide, as well as to 
study the potential role of appendectomy in risk of hematological malignancies of lymphoid 
origin. 
3.2 SPECIFIC AIMS 
 To evaluate the risk of attempted and completed suicide following diagnosis of 
hematological malignancies, and potential effect modification by host factors and 
comorbidity; 
 To study the effect of comorbid diseases on all-cause, cancer-specific and other-cause 
mortality in leukemia and myeloma; 
 To examine the association between specific comorbid diseases with cancer-specific 
mortality in leukemia, myeloma and diffuse large B-cell lymphoma; 
 To study the relationship between comorbidity and lymphoma characteristics, treatment 
selection and mortality in patients with diffuse large B-cell lymphoma; 
 To study the risk of lymphoid neoplasms in patients undergoing appendectomy. 
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4 PATIENTS AND METHODS 
4.1 PATIENTS 
4.1.1 The Swedish national registers 
Study cohorts were created through linkage between the Swedish Cancer Register, the Swedish 
Patient Register, the Longitudinal Integration Database for Health Insurance and Labour 
Market Studies (LISA), the Swedish Cause of Death register and the Swedish Total Population 
register. For study III, the cohort was defined using the national quality register of lymphoma. 
The linkages were completed with help from Statistics Sweden and the National Board of 
Health and Welfare through the unique personal identification numbers assigned to Swedish 
residents, which have been replaced by serial numbers and a code key. 
4.1.1.1 The Swedish Cancer Register 
The Swedish cancer register started in 1958 and covers the total population. By law, all health 
care providers have to report newly diagnosed cancer cases diagnosed in hospitals, clinics or 
laboratories. The register includes data on sex, age, place of residence, type of cancer, date of 
diagnosis, stage (from 2004), hospital and department with approximately 96% coverage. 
4.1.1.2  The Swedish Patient Register 
The Swedish patient register was established regionally in 1964, and covers the whole country 
from1987. The register contains information on dates of admission to and discharge from 
hospitals, main and secondary diagnoses based on ICD codes [140]. Starting in 2001, this 
register now also records outpatient visits in non-primary health care.  
4.1.1.3 LISA 
The Longitudinal Integration Database for Health Insurance and Labor Market Studies (LISA) 
is kept by Statistics Sweden and includes data on education level, income and marital status. 
The register is updated annually and holds data from 1990. 
4.1.1.4  The Swedish Cause of Death Register 
The Cause of Death Register started in 1961 and contains main cause of death, secondary 
causes of death, place, age and date of death [140]. All deaths of registered residents are 
recorded even if they die outside of the country. ICD codes are used to record causes of death 
based on death certificates. 
4.1.1.5 The Swedish Total Population Register 
This register was initiated in 1964 and includes data such as sex, citizenship, date of birth, date 
of death, country of birth, and dates of immigration and emigration [141].  The register covers 
the entire population of Sweden and is updated on a daily basis. 
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4.1.2 Quality register 
4.1.2.1 The national quality register for lymphoma 
The national Swedish quality register for lymphoma was established in 2000 and holds data on 
subtype of lymphoma according to the WHO classification, stage of disease (according to Ann 
Arbor), date of diagnosis, extranodal sites, bulky disease, serum-lactate dehydrogenase (S-LD), 
performance status, B symptoms and primary treatment intent (curative/palliative)[142]. Since 
2007, the register also holds data on primary treatment modality, chemotherapy regimen and 
treatment response. A validation of registered lymphoma characteristics at diagnosis was 
carried out in 2010 through medical record review and showed generally high concordance (80-
90%) (personal communication Dr Szekely, Skåne University Hospital Malmö). 
4.2 STUDY DESIGN 
4.2.1 Study I 
Population: All patients with a first diagnosis of a hematological malignancy 1992 to 2009 at 
15 years of age or older were included in the main study cohort (patients with diagnosis at 
autopsy were excluded) (N=46,309). We also included a random sample of patients >15 years 
of age with solid cancers representing 10% of these patients diagnosed 1992 to 2009 
(N=61,552). For each cancer patient, one comparison individual with the same sex and birth 
year was randomly selected (N=107,736). The comparison individuals further had to be alive 
and free of cancer at the time of the patients’ diagnoses.  
Exposure: The main exposure of interest was a diagnosis of a hematological malignancy 
including ALL, AML, CML, myeloma/plasmocytoma, HL and NHL (including CLL). 
Secondary exposure was a diagnosis of a solid cancer. 
Outcome: Main outcomes were attempted suicide (defined based on hospital admission codes 
in the patient register) or completed suicide (defined based on cause-of-death register codes) 
following a diagnosis of cancer, and in comparison individuals following the date of diagnosis 
of the matched cancer case.  (ICD codes can be found in the supplement to study I). 
Statistical methods: The association between a diagnosis of a hematological malignancy/solid 
cancer and attempted or completed suicide was estimated in a Poisson regression model and 
expressed as incidence rate ratios (IRR) with 95% confidence intervals (CI). The Poisson 
model is a type of linear model with the assumption that the outcome event follows a Poisson 
distribution. Age, sex, migration status, total number of years of education, calendar period of 
diagnosis of cancer, and history of mental disorders were included as the potential confounders 
in the multivariable model. We also tested for interaction effects by introducing interaction 
terms in the model.  
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4.2.2 Study II 
Population: All patients aged >18 years, with a first diagnosis of AML, CML or myeloma 
from 2002 to 2009 in Sweden were included in the cohort except those with a history of 
hematopoietic-cell or solid organ transplantation, or those diagnosed at autopsy (N=8,135). 
Exposure: The Swedish Patient Register was used to collect information on hospitalizations 
and outpatient visits due to comorbid diseases during a period of 5 years prior to the diagnosis 
of leukemia/myeloma. The comorbid diseases included cardiovascular disease, diabetes 
mellitus, cerebrovascular disease, chronic pulmonary disease (CPD), peripheral vascular 
diseases, peptic ulcer disease, rheumatologic disease, renal disease, liver disease, dementia, 
hemiplegia/paraplegia and HIV/AIDS in line with diagnoses listed according to the Charlson 
index and modifications for use in administrative data by Quan et al, with the addition of 
psychiatric disorders. History of rheumatologic and renal diseases during the year leading up to 
the diagnosis of leukemia and myeloma were disregarded. The cancer register was used to 
assess previously diagnosed solid cancers at any time point before the diagnoses of 
leukemia/myeloma. 
Outcome: The Cause-of-Death register was used to obtain date of death and main cause of 
death. Death due to leukemia/ myeloma was classified as cancer-specific death otherwise 
deaths were defined as other-cause deaths. We used the principle outlined by Howlader et al. 
[143] when defining cancer-specific death, classifying also, e.g. leukemia unspecified as 
cancer-specific death in patients with AML or CML. 
Statistical methods: We estimated the association of any comorbid disease history, and 
number of comorbid diseases with all-cause, cancer-specific and other-cause death following a 
diagnosis of leukemia/myeloma in a Poisson regression model, and the association was 
expressed as Mortality Rate Ratios (MRR) with 95% CIs. We also estimated the effect of the 
specific comorbid diseases on survival using all patients without the specific type of comorbid 
disease as reference. The probability of cause-specific and other-cause death in the presence of 
competing risks was estimated for patients aged 60-69, 70-79 and 80-89 years, among men and 
women separately, using flexible parametric survival models with 95% CI to be able to fit time 
dependent and non-proportional effects better. Using flexible parametric model, we could 
calculate the smooth estimates of cause-specific hazards and the cumulative incidence function. 
When we estimated survival in the presence of competing cases of death, cubic splines were 
used to model the log baseline cumulative hazard [144]. 
4.2.3 Study III 
Population: All patients aged >18 years with diffuse large B-cell lymphoma (DLBCL) as the 
first primary hematological malignancy 2004-2009, during the Rituximab era, was defined 
using the national Swedish quality register for lymphoma (N=3,177). Patients diagnosed with 
DLBCL at autopsy or with a history of hematopoietic-cell or solid organ transplantation were 
excluded from the study. 
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Exposure: Through linkage of the study population to the Swedish Patient Register, we 
gathered information on hospital admissions and non-primary outpatient visits with codes of 
comorbid disease (according to modified Charlson index [118, 119] with the addition of 
psychiatric disorders) during a period of 5 years prior to the diagnosis of DLBCL.  
Outcome: The main outcome was lymphoma characteristics at diagnosis (stage, IPI, LD, bulky 
disease and adverse extranodal location), and treatment intent (curative or palliative). 
Secondary outcome was death due to lymphoma or other causes. Main underlying death causes 
and dates of death were collected from the Swedish Cause of Death Register. Patients were 
followed from the date of diagnosis of DLBCL until emigration, death or December 31st 2012, 
whichever occurred first. 
Statistical methods:  Associations with comorbidity and lymphoma characteristics at diagnosis 
and treatment intent were estimated using multinomial regression, a type of logistic regression 
that allows for the prediction of outcome variables with more than two categories. In this 
model, the host, lymphoma and treatment factors were included as outcome factors, and 
comorbid disease history was treated as an explanatory variable (yes/no), further adjusted for 
age and sex at diagnosis. From each model, we predicted the probability of the outcome for 
patients with and without comorbidities, respectively, assuming that age at diagnosis was fixed 
at the mean level in the cohort. Then, we estimated the relative risk ratios (RRR) (also 
interpretable as relative probabilities), of the outcome factors. In the multinomial regression, if 
the outcome is dichotomous, the resulting relative risk in fact represents an odds ratio (OR). As 
a secondary outcome, we assessed the relative risk of death (all-cause, lymphoma-specific, 
other-cause) by comorbidity using Mortality Rate Ratios (MRR) with 95% CIs in a Poisson 
regression model. Analyses were performed among all patients, and separately among patients 
treated with curative intent.  
4.2.4 Study IV 
Population: We identified patients who had undergone appendectomy from 1975 to 2009 in 
Sweden from the Swedish Patient Register (N=337,437). Patients aged 60 years or older at 
appendectomy, with a history of lymphoid neoplasms before appendectomy, or with less than 
one year of follow-up were excluded from the study. 
Exposure: Patients treated with appendectomy were first subdivided in two major exposure 
groups: those who had appendectomy alone and those who had appendectomy performed in 
parallel with other surgical procedures. Next, the medical discharge diagnoses codes were 
considered (including appendicitis, perforated/abscessed or not, mesenteric lymphadenitis and 
other diagnoses). 
Outcome: using linkage with the Swedish Cancer Register, we identified first incident 
diagnoses of lymphoid neoplasms including NHL overall (including CLL), HL, myeloma 
(multiple myeloma, plasmocytoma) or ALL. Patients with lymphoid neoplasms diagnosed 
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during the first year after appendectomy were excluded. Additionally, using Systematized 
Nomenclature of Medicine (SNOMED) codes available from 1993 and onwards, major 
subtypes of NHL (DLBCL, follicular lymphoma, other B-cell NHL as one group and T-cell 
lymphoma) were classified. 
Statistical methods: We calculated the relative risk of lymphoid neoplasms compared with the 
corresponding stratum-specific incidences in the general population using standardized 
incidence ratios (SIRs) with 95% CI, under the assumption that cases followed a Poisson 
distribution. The patients were thus followed from one year after appendectomy until the date 
of diagnosis of a lymphoid neoplasm, first emigration date, death or December 31st 2009 (end 
of follow up), whichever occurred first. Separate analyses were performed among individuals 
aged <20 years of age at appendectomy. 
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Table 2. Overview of patients and methods included in studies I-IV 
 Study I Study II Study III Study IV 
Type of study Register-based cohort study (study I-IV) 
Number of patients Leukemia: 7,160 
Myeloma: 8,444 
Lymphoma: 30,705 
Other cancers: 61,552 
AML: 2,550 
Myeloma: 4,584 
CML: 1,000 
 
DLBCL: 3177 337,437 
Number of 
comparators 
107,736 - - General population 
Ages ≥ 15 ≥ 18 ≥ 18 All ages 
Study period 1992-2009 2002-2009 2004-2009 1975-2009 
Data sources Cancer Register 
Patient Register 
LISA 
Cause of Death Register 
Cancer Register 
Patient Register 
LISA 
Cause of Death Register 
Lymphoma Register 
Cancer Register 
Patient Register 
LISA 
Cause of Death Register 
Cancer Register 
Patient Register 
Exposure Cancer Comorbid disease Comorbid disease Appendectomy 
Outcome Suicidal behaviors All cause and cancer 
specific mortality 
Treatment type, IPI, 
Stage, Performance 
status, all cause and 
cancer specific mortality 
Lymphoid neoplasms 
Statistical models Poisson regression Poisson regression 
Flexible parametric 
model 
Poisson regression 
Multinomial regression 
 
Poisson regression 
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4.3 ETHICAL CONSIDERATIONS 
All four studies were approved by the Regional Board of the Ethical Committee, Stockholm. 
(Study I: 2005/726-31, 2009/587-32, 2014/1026-32; study II-III: 2007/1335-31/4, 2010/1624-
32; study IV: 2014/94-31/2). All studies are register-based studies and, according to present 
Swedish regulations, individual informed consent is not needed in order to access register 
data for research purposes. The researchers have not had access to personal identifications 
numbers, only to pseudonymised data. This coded data has been handled in line with 
applicable rules and regulations at the Karolinska Institutet in order to preserve data integrity.   
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5 RESULTS 
5.1 STUDY I 
For details, please see the appended publication (PMID: 24789427). In summary, in the 
identified cohort of 46,309 patients with hematological malignancies, we found a statistically 
significant 45% increased risk of attempted suicide (IRR=1.45, 95% CI =1.18-1.77) and a 2-
fold increased risk of completed suicide (IRR=2.06, 95% CI=1.51-2.81) (Table 2) compared 
with cancer free subjects.  In analysis of subgroups of patients with hematological malignancy 
subtypes, we observed significantly increased risks of attempted suicide among patients with 
myeloma (IRR=2.13, 95% CI=1.39-3.26) and lymphoma (IRR=1.34, 95% CI=1.07-1.69). For 
completed suicide, the adjusted risk was increased among patients with lymphoma (IRR=1.87, 
95% CI=1.31-2.67), and myeloma (IRR =3.52, 95% CI=2.05-6.03) compared with the cancer-
free cohort. For patients with leukemia, point estimates of risk of attempted and completed 
suicide were increased to a similar level as patients with lymphoma, but the estimates were not 
statistically significant. Due to small numbers, it was not meaningful to stratify patients further 
by subtype of leukemia (AML, CML). Risk of attempted and completed suicide among patients 
with hematological malignancies overall (compared with cancer-free individuals) was 
increased to a similar extent as in other cancer patients when treated as one group. In the 
sample of other solid cancer patients, risk of attempted suicide was 48% increased (IRR=1.48, 
95% CI=1.24-1.77), and risk of completed suicide was 89% increased (IRR=1.89, 95% 
CI=1.42-2.51) compared with cancer-free individuals. 
Table 3. Relative risk1 of attempted and completed suicide among patients with hematological 
malignancies, and in a random sample of patients with other types of cancer, compared with 
cancer-free individuals. 
 Attempted suicide Completed suicide 
No. of 
events 
Incidence 
/10,000 py 
IRR (95% CI)1 No. of 
events 
Incidence 
/10,000 py 
IRR (95% CI)1 
Cancer free 360 4.25 1.00 125 1.44 1.00 
All hematological 
malignancies 
146 6.86 1.45 (1.18-1.77) 63 2.95 2.06 (1.51-2.81) 
Leukemia 17 7.70 1.42 (0.87-2.32) 5 2.26 1.82 (0.72-4.59) 
Myeloma 24 8.30 2.13 (1.39-3.26) 15 5.18 3.52 (2.05-6.03) 
Lymphoma 105 6.49 1.34 (1.07-1.69) 43 2.65 1.87 (1.31-2.67) 
Other cancers 192 6.16 1.48 (1.24-1.77) 88 2.82 1.89 (1.42-2.51) 
1 Incidence Rate ratios (IRR) with 95% confidence intervals (CI), adjusted for sex, age, calendar period, education, 
migration status and history of mental disorders before diagnosis of cancer. 
History of mental disorders or suicide attempts was associated with approximately 15 to 30-
fold increased risks of attempted as well as completed suicide compared with cancer-free 
individuals without such history (Table 3), although formal tests for interaction were not 
statistically significant. Importantly, increased risks were also observed among patients with 
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hematological malignancies without records of such comorbidity. A more pronounced 6.5-fold 
increased risk of completed suicide was also noted among immigrants with hematological 
malignancies compared with cancer-free native residents (p for interaction 0.03).  
Table 4. Relative risk* of attempted or completed suicide by potential effect modifying factors 
among patients with hematological malignancies compared with cancer-free individuals 
 Attempted suicide Completed suicide 
No. of 
events 
Incidence 
/10,000 py 
IRR (95% CI) No. of 
events 
Incidence 
/10,000 py 
IRR (95% CI) 
History of mental disorder 
   No - cancer free 268 3.19 1.00 105 1.25 1.00 
   Yes - cancer free 92 34.7 10.9 (8.57-13.9) 20 7.40 6.35 (3.94-10.2) 
   No - cancer  103 5.00 1.47 (1.16-1.85) 50 2.42 1.90 (1.35-2.68) 
   Yes - cancer 43 66.6 19.5 (14.0-27.2) 13 19.5 16.4 (9.12-29.5) 
History of attempted suicide 
   No - cancer free 304 3.54 1.00 117 1.40 1.00 
   Yes – cancer free 56 78.8 19.8 (14.7-26.6) 8 10.7 9.09 (4.42-18.7) 
   No - cancer 128 6.07 1.61 (1.30-1.99) 58 2.74 1.97 (1.43-2.73) 
   Yes - cancer 18 110 28.1 (17.2-45.9) 5 28.5 23.7 (9.68-57.9) 
1 Incidence Rate ratios (IRR) with 95% confidence intervals (CI), adjusted for sex, age, calendar period, education 
and migration status. 
5.2 STUDY II 
For details, please see the appended publication (PMID: 26537111). Among all patients, 40% 
were classified as having at least one comorbid disease. Patients with AML had the highest 
proportion (43%) and also the highest median age at diagnosis (72 years). Among patients 
above 80 years of age at diagnosis, the majority had a history of comorbid disease (AML 59%, 
CML 59%, myeloma 52%). Any comorbidity was associated with increased risks of all-cause 
as well as cancer-specific death among patients with AML and myeloma, and with a borderline 
increased risk among patients with CML. Renal disease was associated with an increased risk 
of cancer-specific death in all patient groups (Figure 1). 
Acute myeloid leukemia (AML) 
More specifically, in AML patients, a history of cerebrovascular, rheumatologic, renal, liver or 
psychiatric disease or dementia, was observed to be associated with a significantly higher 
AML-specific mortality compared with patients without the specified comorbid diseases in 
question. Using estimates from flexible parametric survival models to assess the stacked 
cumulative probability of cancer-specific and other-cause death accounting for competing risks 
during the first 5 years of follow-up, cancer-specific death dominated in men and women 60-89 
years, irrespective of comorbidity. The cumulative probability of cancer-specific death in 
patients with comorbid disease was higher than in patients without comorbid disease in age 
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groups 60-69 and 70-79 years, but there was no difference by comorbidity in patients 80+ years 
of age.   
Chronic myeloid leukemia (CML) 
CML patients with a history of renal disorders had a significantly increased CML-specific 
mortality. Other diseases including cardiovascular, rheumatologic and liver disease were 
associated with nominally increased risks but were non-significant, perhaps due to small 
numbers. Having a history of comorbid disease was associated with higher 5-year cumulative 
probability of cancer-specific death among men 60-69 years and women 80-89 years. In other 
ages, no significant differences between patients with and without comorbid disease were 
observed. Among male CML patients >70 years of age, other-cause deaths were more common 
than CML-specific deaths.  
Myeloma 
Patients with myeloma and prior renal disease, cardiovascular diseases, cerebrovascular 
diseases, CPD, psychiatric diseases and dementia were at increased risk of myeloma-specific 
mortality compared to patients without these disorders, respectively. The probability of 
myeloma-specific death within 5 years after diagnosis of myeloma was higher in patients with 
comorbid disease than in those without comorbid disease in both sexes and all age groups 
studied (60-89 years). 
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Figure 1. MRR for all-cause and cancer-specific death by type of comorbid disease 
MRR: Mortality rate ratios adjusted for age (in 10 year intervals), country of birth, time since diagnosis, calendar 
year of diagnosis and number of comorbid diseases, sex and education level except when main effects of these 
factors were estimated AML: acute myeloid leukemia CML: chronic myeloid leukemia CPD: Chronic pulmonary 
disease 
*Because of few patients with hemiplegia/paraplegia (n=49) and HIV/AIDS (n=2) overall, and with liver disease in 
CML, results for these groups are not presented.  
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5.3 STUDY III: 
For details, please see the appended unpublished manuscript. Among the 3,177 patients with 
DLBCL, 40% of the patients had a history of at least one of the comorbid diseases assessed, 
and 13% had a history of two or more diseases. Any comorbidity was associated with higher 
relative probability of presenting with low performance status, and high international 
prognostic index (IPI) score compared with patients without comorbidity at diagnosis of 
DLBCL. There were no apparent differences in the relative distribution by stage at diagnosis, 
elevated LD or unfavorable extranodal locations by comorbidity. Further, there was a large 
difference in treatment intent. Among patients without comorbidity, 86% of the patients were 
selected for primary treatment with curative intent, whereas only 68% of the patients with 
comorbid disease received primary curative treatment (RRR=0.48, 95%CI=0.38-0.60).  
Table 5. Relative risk (odds ratio, OR) of being diagnosed with stage III-IV diffuse large B-cell 
lymphoma (DLBCL) versus stage I-II, and being selected for treatment with curative versus 
palliative intent among patients with specific types of comorbid diseases compared with no 
comorbid disease. 
 All patients 
Stage III-IV versus I-II Curative versus palliative 
treatment intent 
 OR (95% CI) OR (95% CI) 
Type of comorbid disease  
  No comorbid disease 1.00 (reference) 1.00 (reference) 
  Solid cancer 0.87 (0.69-1.10) 0.56 (0.40-0.77) 
  Cardiovascular disease 0.83 (0.60-1.15) 0.50 (0.33-0.76) 
  Diabetes 0.83 (0.61-1.12) 0.77 (0.50-1.20) 
  Cerebrovascular disease 0.79 (0.54-1.11) 0.66 (0.41-1.05) 
  Chronic pulmonary disease 1.24 (0.85-1.82) 0.40 (0.24-0.66) 
  Peptic ulcer disease 1.00 (0.65-1.53) 0.89 (0.48-1.65) 
  Rheumatologic disease 1.11 (0.71-1.75) 0.59 (0.31-1.11) 
  Peripheral vascular disease 1.00 (0.57-1.77) 0.61 (0.30-1.24) 
  Psychiatric disorders 1.66 (0.89-3.08) 0.27 (0.12-0.59) 
  Liver disease 1.61 (0.79-3.27) 0.24 (0.10-0.57) 
  Renal disease 1.18 (0.59-2.38) 0.41 (0.17-0.97) 
  Dementia 0.41 (0.16-1.07) 0.19 (0.07-0.48) 
  Hemiplegia/Paraplegia 0.71 (0.28-1.82) 0.34 (0.10-1.20) 
 
Dementia, psychiatric disorders, liver disease, chronic pulmonary disease, cardiovascular 
disease and solid cancer were strongly associated with lower probability of receiving curative 
treatment compared with those without comorbid disease.  
Among all patients, comorbidity was associated with risk of all-cause, lymphoma-specific as 
well as other-cause death (Table 6), likely mediated by differences in treatment intent. Among 
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patients selected for treatment with curative intent, comorbidity was associated with all-cause 
and other-cause deaths, but not with lymphoma-specific deaths (Table 6).   
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Table 6. Mortality rate ratios (MRR)* for all-cause, lymphoma-specific and other-cause death by number of comorbid diseases, host and 
disease characteristics among diffuse large B-cell lymphoma (DLBCL) patients diagnosed between 2004 to 2009. MRRs are presented 
among all patients, and separately among patients treated with curative intent.  
  ALL PATIENTS  PATIENTS TREATED WITH CURATIVE INTENT 
All-cause death 
Lymphoma–specific 
death 
Other-cause death All-cause death 
Lymphoma–specific 
death 
Other-cause death 
  MRR (95% CI) MRR (95% CI) MRR (95% CI)  MRR (95% CI) MRR (95% CI) MRR (95% CI) 
No. of comorbid diseases 
   0  1.00 1.00 1.00  1.00 1.00 1.00 
   1  1.34 (1.17-1.53) 1.25 (1.06-1.46) 1.61 (1.25-2.08)  1.20 (1.03-1.41) 1.11 (0.92-1.34) 1.43 (1.07-1.91) 
   2+  1.73 (1.48-2.03) 1.43 (1.18-1.73) 2.81 (2.12-3.73)  1.62 (1.34-1.97) 1.21 (0.95-1.55) 2.91 (2.12-4.01) 
Sex 
   Men  1.00 1.00 1.00  1.00 1.00 1.00 
   Women  0.87 (0.78-0.98) 0.84 (0.74-0.96) 0.96 (0.77-1.20)  0.88 (0.77-1.01) 0.85 (0.72-0.99) 0.97 (0.76-1.24) 
Education level 
   0-9  1.00 1.00 1.00  1.00 1.00 1.00 
   10-12  0.90 (0.79-1.03) 0.85 (0.73-0.99) 1.05 (0.82-1.35)  0.92 (0.79-1.07) 0.89 (0.74-1.07) 0.98 (0.74-1.29) 
   >12  0.96 (0.81-1.13) 0.91 (0.75-1.10) 1.08 (0.79-1.45)  1.02 (0.85-1.23) 1.01 (0.81-1.25) 1.02 (0.72-1.44) 
Performance status 
 Asymptomatic  1.00 1.00 1.00  1.00 1.00 1.00 
 Symptoms – ambulatory  1.62 (1.39-1.89) 1.79 (1.48-2.17) 1.34 (1.02-1.76)  1.70 (1.44-2.02) 1.94 (1.57-2.40) 1.34 (0.99-1.79) 
 <50% in bed  2.20 (1.80-2.69) 2.44 (1.92-3.11) 1.85 (1.26-2.70)  2.05 (1.62-2.60) 2.24 (1.68-2.99) 1.86 (1.20-2.88) 
 >50% in bed/bedbound 4.54 (3.78-5.44) 5.35 (4.31–6.63) 2.85 (1.95-4.17)  3.39 (2.71-4.23) 4.00 (3.08-5.20) 2.20 (1.40–3.47) 
S-lactate dehydrogenase (LD) 
  Normal  1.00 1.00 1.00  1.00 1.00 1.00 
  Elevated  1.41 (1.23-1.61) 1.50 (1.28-1.77) 1.21 (0.95-1.55)  1.40 (1.19-1.64) 1.52 (1.25-1.85) 1.17 (0.89-1.54) 
Bulky disease 
  No  1.00 1.00 1.00  1.00 1.00 1.00 
  Yes  1.15 (1.00-1.31) 1.21 (1.03-1.41) 0.97 (0.73-1.30)  1.19 (1.02-1.40) 1.26 (1.05-1.51) 1.03 (0.74-1.42) 
Stage** 
  Stage I  1.00 1.00 1.00  1.00 1.00 1.00 
  Stage II  0.90 (0.74-1.09) 0.98 (0.76-1.26) 0.82 (0.60-1.13)  0.82 (0.66-1.02) 0.84 (0.63-1.13) 0.82 (0.58-1.17) 
  Stage III  1.05 (0.85-1.29) 1.28 (0.99-1.66) 0.78 (0.54-1.13)  1.01 (0.80-1.27) 1.16 (0.86-1.55) 0.86 (0.57-1.29) 
  Stage IV  0.92 (0.76-1.12) 1.20 (0.94-1.53) 0.53 (0.37-0.75)  0.84 (0.68-1.05) 1.07 (0.81-1.41) 0.51 (0.34-0.77) 
Major extranodal disease† 
No  1.00 1.00 1.00  1.00 1.00 1.00 
Yes  1.74 (1.50-2.03) 1.73 (1.45-2.07) 1.79 (1.31-2.44)  1.66 (1.39-1.99) 1.67 (1.36-2.06) 1.65 (1.15-2.35) 
*MRR=Mortality rate ratios adjusted for age, country of birth, time since diagnosis, calendar year of diagnosis, sex, education level, performance status, stage, LD, bulky disease, extranodal disease and 
comorbidity 
**Stage I: AA1, PeI; Stage II: AA2, PeII, PeII1, PeII2; Stage III: AA3; Stage IV: AA4 
† Extranodal locations known to be associated with poor prognosis (including central nervous system (CNS), bone marrow, lung and gastrointestinal sites including liver) 
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5.4 STUDY IV 
For details, please see the appended publication (PMID: 26652908). Among the 337,437 
individuals appendectomized before the age of 60 years, the majority (82%) were also younger 
than 40 years at surgery, and 42% were younger than 20 years. We found no increased risk of 
NHL, HL, CLL, myeloma or ALL associated with appendectomy per se relative to the general 
population in Sweden. In a stratified analysis, patients diagnosed with appendicitis after 
appendectomy were at a statistically significant increased risk of HL (SIR=1.29, 95% CI=1.07-
1.54), based on 122 observed HL cases. In patients appendectomized from 1993 and onwards 
where risks of lymphoma subtypes could be classified in more detail, an increase risk was noted 
for the nodular sclerosis subtype of HL in association with appendicitis (SIR=1.55, 95%CI=1.01-
2.27). An increase was also noted for HL among individuals appendectomized below the age of 20 
years. A statistically significant risk increase was also noted for myeloma among men. 
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Table7. Relative risk* of lymphoid neoplasms** among appendectomized patients <60 years of age stratified by sex, age, duration of 
follow-up, calendar period of appendectomy and medical diagnoses 1975-2009 in Sweden 
 NHL HL CLL Myeloma ALL 
 N SIR (95%CI) N SIR (95%CI) N SIR (95%CI)  N SIR (95%CI) N SIR (95%CI) 
Overall 448 0.97 (0.88-1.06) 144 1.14 (0.96-1.34) 93 0.87 (0.70-1.06) 156 1.14 (0.96-1.33) 45 1.10 (0.80-1.47) 
Sex    
   Men 251 0.90 (0.79-1.02) 80 1.15 (0.91-1.43) 62 0.89 (0.68-1.14) 102 1.24 (1.01-1.50) 23 0.97 (0.61-1.45) 
  Women 197 1.07 (0.92-1.23) 64 1.13 (0.87-1.44) 31 0.83 (0.56-1.18) 54 0.99 (0.74-1.29) 22 1.28 (0.80-1.93) 
Age at appendectomy    
  0-19 years 56 0.94 (0.71-1.22) 76 1.18 (0.93-1.48) 2 0.76 (0.09-2.76) 5 1.00 (0.32-2.33) 23 1.08 (0.68-1.61) 
  20-39 years 166 1.00 (0.85-1.16) 50 1.11 (0.82-1.46) 23 0.74 (0.47-1.11) 44 1.06 (0.77-1.42) 13 1.07 (0.57-1.83) 
  40-59 years 226 0.95 (0.83-1.09) 18 1.08 (0.64-1.70) 68 0.93 (0.72-1.17) 107 1.18 (0.97-1.42) 9 1.20 (0.55-2.28) 
Duration of follow-up    
  1-4 years 71 1.04 (0.81-1.31) 44 1.25 (0.91-1.68) 18 1.58 (0.94-2.50) 25 1.57 (1.02-2.32) 13 0.91 (0.49-1.56) 
  5-9 years 81 1.01 (0.80-1.25) 35 1.06 (0.74-1.48) 10 0.64 (0.31-1.17) 16 0.75 (0.43-1.22) 8 0.87 (0.38-1.71) 
  10-14 years 84 0.97 (0.77-1.20) 31 1.22 (0.83-1.74) 16 0.85 (0.49-1.38) 30 1.20 (0.81-1.71) 9 1.39 (0.64-2.64) 
  15-26 years 170 0.97 (0.83-1.13) 27 0.96 (0.63-1.40) 39 0.84 (0.60-1.15) 64 1.13 (0.87-1.44) 12 1.31 (0.68-2.29) 
  26+ years 42 0.81 (0.58-1.10) 7 1.50 (0.60-3.09) 10 0.67 (0.32-1.23) 21 1.15 (0.71-1.76) 3 1.50 (0.31-4.37) 
Calendar period of appendectomy 
  1975-1989 322 0.94 (0.84-1.05) 92 1.10 (0.89-1.35) 70 0.86 (0.67-1.09) 111 1.05 (0.87-1.27) 28 1.08 (0.71-1.55) 
  1990-1999 102 1.04 (0.85-1.27) 41 1.21 (0.87-1.64) 19 0.90 (0.54-1.40) 39 1.50 (1.07-2.05) 15 1.31 (0.73-2.16) 
  2000-2009 24 1.02 (0.65-1.52) 11 1.25 (0.62-2.24) 4 0.88 (0.24-2.25) 6 1.02 (0.37-2.21) 2 0.57 (0.07-2.05) 
Medical diagnosis    
  Appendicitis only 327 0.92 (0.83-1.03) 122 1.29 (1.07-1.54) 69 0.83 (0.65-1.05) 116 1.10 (0.91-1.32) 34 1.10 (0.76-1.54) 
  Appendicitis with other    
medical diagnoses 
36 1.35 (0.95-1.87) 4 0.69 (0.19-1.78) 8 1.21 (0.52-2.39) 11 1.30 (0.65-2.33) 4 2.05 (0.56-5.24) 
  Mesenteric lymphadenitis 19 1.27 (0.77-1.99) 9 0.92 (0.42-1.74) 3 1.70 (0.35-4.96) 4 1.51 (0.41-3.88) 3 0.95 (0.20-2.78) 
  Other diagnoses 66 0.98 (0.76-1.24) 9 0.57 (0.26-1.08) 13 0.83 (0.44-1.43) 25 1.21 (0.78-1.78) 4 0.78 (0.21-1.99) 
Appendicitis spectrum    
  Non-perforated 293 0.94 (0.83-1.05) 111 1.28 (1.05-1.54) 66 0.92 (0.71-1.17) 107 1.17 (0.96-1.41) 32 1.15 (0.79-1.62) 
  Perforated/ abscessed 70 1.03 (0.80-1.30) 15 1.09 (0.61-1.80) 11 0.61 (0.30-1.09) 20 0.89 (0.54-1.37) 6 1.22 (0.45-2.65) 
* Relative risk was assessed as the standardized incidence ratio (SIR) with 95% confidence interval (CI)** Also includes 6 patients with unspecified lymphoma. 
NHL=Non-Hodgkin lymphoma, HL=Hodgkin lymphoma, CLL=Chronic lymphocytic leukemia, ALL=Acute lymphoblastic leukemia. Patients with diagnosis of a 
lymphoid neoplasm during the first year after appendectomy were excluded.  
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6 DISCUSSION 
6.1 INTERPRETATION OF FINDINGS 
6.1.1 Study I 
In this study, risks of attempted and completed suicide were significantly increased in 
patients diagnosed with hematological malignancies compared with cancer free individuals, 
and the risks were most pronounced for patients with myeloma. Risk levels among 
hematological malignancy compared to cancer free individuals were similar to those among 
solid cancer patients compared to cancer-free individuals. Risks in patients with myeloma 
appeared to be higher than among other solid cancer patients on average, although no direct 
formal comparison was made contrasting these patient groups 
The association between a diagnosis of a hematological malignancy and risk of completed 
suicide has been investigated in several previous studies [17-25]. A few have attempted to 
estimate risk in patient subgroups of hematological malignancies including myeloma, AML, 
HL and NHL [21, 22]. In line with our findings, Kendal et al. noted a higher rate of 
completed suicide for myeloma than leukemia and lymphoma [24]. Mental disorders, severe 
illness and advanced stage of disease are known risk factors for suicide in the general 
population and also in cancer patients [23, 100, 145-149]. The higher risk of suicide in 
myeloma could be associated with the often severe symptoms of myeloma such as bone pain 
and functional disability and the incurable prognosis [150-153], since pain, physical 
symptoms and prognosis are plausible triggers for suicide ideation [17]. Health care 
personnel working with hematological malignancy patients (as well as those working with 
other cancer patients) should be aware of the increased risk of attempted and completed 
suicide in patients with increased susceptibility (previous mental disorders and suicide 
attempts, immigrants) as well as those with bad prognosis and disabling symptoms (among 
hematological malignancies myeloma in particular). 
6.1.2 Study II 
Comorbidity is an established predictor of prognosis in solid cancers [109-113] and 
hematological malignancies [8-13] especially among patients eligible for hematopoietic stem 
cell transplantation [14-16]. Previous studies of the association of comorbidity with 
hematological malignancy outcomes have often focused on overall survival rather than 
progression-free or cancer-specific survival, and have also often been too small in size to 
investigate associations with separate comorbid disorders. 
6.1.2.1 AML 
A favorable outcome of treatment in AML, i.e. complete remission and long-term survival 
can be achieved in a subgroup of patients through intensive chemotherapy, the tolerability 
and administration of which depends on age and performance status [154, 155]. In previous 
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studies on elderly (65+ years) AML patients, a worse overall survival has been reported for 
patients with comorbid diseases using the Charlson comorbidity index (CCI)[10-12, 65, 156, 
157]. Etienne et al. also showed that comorbid diseases (CCI>1) are predictors of complete 
remission [12] and others reported a decrease in the chances of receiving intensive 
chemotherapy with increasing number of comorbid disease [13, 157]. Potential differences in 
outcome by type of comorbidity was not explored in these studies beyond the weighting of 
disorders built into the CCI. The specific comorbidities associated with AML-specific 
mortality in this study are plausibly linked with a lower tolerance for intensive remission-
induction regimens at an organ-level (renal and liver disease) or with a presumed lower 
tolerability and compliance to intensive chemotherapy in general (cerebrovascular and 
psychiatric disease, dementia) [13]. On the other hand, common comorbidities such as 
diabetes, cardiovascular disease and previous cancer were not significantly associated with a 
worse treatment outcome, although large individual variations are of course likely depending 
on the severity of the disease. Contrary to a wide-spread belief that comorbidity represents a 
clinical challenge mostly in the oldest patients, we further showed that any comorbidity was 
associated with a higher probability of AML-specific death mainly among patients aged 60 to 
69 years, but not among patients 80-89 years. This finding likely reflects differences in 
treatment intentions and tumor biology by age [158]. 
6.1.2.2 CML 
Although tyrosine kinase inhibitors have improved survival in CML in the 21st century, 5-
year survival is still around 60% [69, 159]. Previous studies of the impact of comorbid 
disease on CML prognosis in the tyrosine kinase era, suggest a major effect of aging and 
increased frequency of other-cause deaths rather than CML-specific deaths [160]. Another 
concern is that patients with comorbid disease may not eligible to start tyrosine kinase 
inhibitors. We observed that prior renal disease in particular was associated with increased 
CML-specific death, which may be mediated through dose reductions or caution to prescribe 
tyrosine kinase inhibitors [67, 161]. Our findings of a negative impact of comorbid disease on 
overall survival was in line with previous studies [156, 160, 162, 163] but additionally 
showed that other-cause deaths outnumbered CML-specific deaths regardless of comorbidity 
in male patients above the age of 70 years, which may have implications for treatment 
decisions at an individual level. On the other hand, women were more likely to die of CML 
rather than other causes up to 89 years of age, potentially indicating under treatment in these 
patients [159]. 
6.1.2.3  Myeloma 
Survival in myeloma patients has improved in later years due to several factors including 
more intensive treatment schemes and hematopoietic-cell transplantation as well as better 
supportive care [164, 165]. Comorbidity has been reported to be associated with overall 
survival in previous studies [166, 167]. According to these previous reports, renal disorder 
and lung disease are particularly important determinants for myeloma outcome [166-168]. 
Our results from study of ~4500 myeloma patients confirm the prognostic implications of 
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history of renal and pulmonary disease, in addition to pointing to associations with 
cardiovascular and cerebrovascular disease, dementia and psychiatric disorders.  
6.1.3 Study III 
In our study, patients with a history of comorbid diseases presented with worse performance 
status and higher IPI score and lower chance of receiving curative treatment at DLBCL 
diagnosis, than other patients.  
DLBCL patients with comorbid disease have been shown in some previous studies to have 
decreased overall survival [112, 169-173]. One study also showed a higher likelihood of 
receiving palliative treatment in patients with higher adult comorbidity-27 score disease 
[170]. Another study on DLBCL patients noted a higher risk of toxicity in patients with high 
Charlson comorbidity index [169]. In our study, comorbid disease was further associated with 
increased risk of lymphoma-specific death, in line with the lower treatment response rate also 
reported in two previous smaller investigations [112, 171]. However, most previous studies 
have been small (median N=165, range 41-387) as reviewed by Terret et al. in 2015 [174], 
and have not evaluated treatment selection or outcome in relation to specific comorbid 
diseases. 
Cardiovascular and chronic pulmonary disorders and dementia were associated both with 
selection of palliative rather than curative treatment, as well as with lymphoma-specific 
death. In a questionnaire based study, cognitive disorders and functional status affected 
hematologists’ treatment selection [175] supporting our findings. Association between 
cardiovascular disorders and lymphoma-specific death points to need the less cardiotoxic 
treatments. Optimizing the patients with cardiovascular disorders before treatment with 
cardiotoxic agents like doxorubicin may also be helpful [176]. 
6.1.4 Study IV 
Overall, we did not observe any strong associations between appendectomy and excess risk 
of lymphoid neoplasms, although we did find an increased risk of HL in patients diagnosed 
with appendicitis rather than appendectomy per se. We also observed an increased risk of 
myeloma among men, which was however confined to the first few years of follow up and 
may be explained by surveillance bias. 
In the 1960s, two studies reported an association between appendectomy and risk of HL [3, 
4]. Later, in 2009, Cozen et al. also reported a positive association in a case-control study 
among twins HL [7]. In the 1960s-1980s three other studies reported no association between 
appendectomy and risk of HL [130-132]. In 1998, Mellemkjaer et al. in a large register-based 
cohort did not observe relation between appendectomy and risk of leukemia, myeloma, HL 
and NHL [5]. However, Cope et al. [6] reported a border-line significantly increased risk of 
NHL in appendectomized children and more evidently in patients diagnosed as appendicitis 
[6].  
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Given the result of previous studies [5, 131, 177], and our findings, there is on the whole no 
evidence of associations between appendectomy and risk of lymphoid neoplasms except the 
possible relation between appendicitis and HL. Appendix is a closed-end lumen rich in 
lymphoid tissue [178, 179] and microbial agents, and is therefore at risk of local infection and 
inflammation. Patients with chronic inflammation in the setting of autoimmune diseases are 
at a higher risk of HL [180-182]. Also, the Epstein-Barr virus (EBV), an established factor in 
the etiology of HL [183], has been found in appendix [184]. An increased risk of appendicitis 
has also been reported in teenagers following  infectious mononucleosis [185]. Genetic 
variation in the HLA-DRB1 region has been linked with several inflammatory conditions and 
infections [186-188] as well as with risk of EBV-negative classical HL [189, 190]. Hence the 
higher risk of HL in appendicitis might be explained by possible biologic mechanisms or 
through shared genetic susceptibility.  
6.2  METHODOLOGICAL CONSIDERATIONS 
6.2.1 Study I 
In this study, we assembled a large cohort of patients with hematological malignancies, and 
carefully matched to population comparators with the same birth year, and sex and who were 
alive and cancer-free at the time of the cancer diagnosis of the case. The large size of the 
study overall ensured sufficient number of events to adjust for several possible confounders 
for which data was also available (education level, mental disorders, migration status). 
However, although the number of events was fairly large overall, estimates of relative risk 
became imprecise in some subgroup analyses, notably for patients with leukemias, and also 
hampered detailed studies of interaction. Also, we may have a problem of misclassification of 
the outcome, especially of attempted suicide, in that hospital admissions for illness associated 
with suicide attempts may have been interpreted and coded as something else. Also, 
sometimes, people may not seek health care for attempted suicide. 
6.2.2 Study II 
The main limitation of this study was lack of information about more refined molecular 
subtypes of AML carrying prognostic information, clinical patient-related factors such as 
performance status and treatment-related factors. It is not entirely clear however, to what 
extent such factors could represent confounding factors or rather effect modifying factors in 
the association between comorbidities and hematological malignancy outcome. For example, 
performance status at leukemia/myeloma diagnosis is likely influenced both by comorbid 
diseases and the malignancy itself.  
To minimize the misclassification bias due to possible error in reporting cause of death in 
different calendar periods we adjusted the analysis for calendar period. Although the quality 
of the cause of death register has been found to be generally high among cancer patients, 
some leukemia/myeloma deaths may have been erroneously classified as other cause death 
and vice versa, making exact proportions uncertain. Also, researchers may use different 
definitions of cancer-specific as opposed to other-cause deaths. Our aim was to define deaths 
  35 
as cancer-specific when death was a result of progressive malignancy, and all other deaths as 
due to other causes. However, other-cause deaths then include a mix of deaths due to 
treatment toxicity (indirectly cancer-related) and unrelated deaths.   
The assessment of comorbidity histories through the Patient register has also resulted in some 
misclassification and misrepresentation of the whole spectrum of comorbid disorders, since 
many milder comorbid diseases are managed primarily in primary health care not captured by 
this register. Hence, the results are likely to represent associations with comorbidities towards 
the severe end of the spectrum. 
6.2.3 Study III 
In this study, we had access to detailed clinical data through the national quality register for 
lymphoma, with improved possibility to control for confounding as well as to investigate 
mediating factors of worse outcomes. The small number of patients for some groups of 
comorbidities is a source of low power and implies a risk of missing true associations.  
Apart from some possible misclassification comorbid disease and causes of death as 
discussed above, the clinical data may also have been misclassified to some extent. However, 
in an unpublished validation study (personal communication Dr Szekely), high concordances 
were found for most factors relating to lymphoma characteristics at presentation.   
6.2.4 Study IV 
The major concern with this study is the large number of analyses performed and estimates 
presented. Given the multiple comparisons, some significant results may have arisen due to 
chance alone. However, the increased risk, observed for HL, was strengthened by biological 
plausibility. Also, the lack of information on subtypes of NHL and HL through snomed codes 
limited the analyses of subtype-specific risks to 1993-2009, which reduced the power for 
these analysis.  
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7 CONCLUSIONS AND FUTURE PERSPECTIVES 
7.1 CONCLUSIONS 
 Risk of attempted and completed suicide is increased in patients diagnosed with 
myeloma and lymphoma. 
 Subgroups of patients with hematological malignancies (as well as other cancer 
patients) should be monitored for suicidal ideation based on individual susceptibility 
(e.g., mental comorbidity) and symtoms/prognosis (e.g. myeloma).  
 Patients with comorbidity prior to AML, CML and myeloma had higher all-cause as 
well as cancer-specific mortality compared with patients without comorbidity. 
 Comorbidities associated with organ failure (most importantly renal disease) or 
cognitive function (cerebrovascular and psychiatric diseases and dementia) were 
associated with worse outcomes in several hematological malignancy subtypes.  
 In patients diagnosed with DLBCL, a history of comorbid disease was associated with 
a lower likelihood of receiving curative treatment. 
 In patients with DLBCL treated with curative intent, comorbid disease history was 
associated with all-cause but not lymphoma-specific death. 
 Appendicitis but not appendectomy per se may be associated with a small increased 
risk of HL, but otherwise there’s little evidence that appendectomy is associated with 
risk of lymphoid malignancies. 
7.2 FUTURE PERSPECTIVES   
 Patients diagnosed with hematological malignancies and other cancer forms are at 
risk of suicide. Intervention studies are needed in order to evaluate how we best can 
monitor, prepare and support the patients to reduce risk of suicidal events. 
 Future prognostic indices in patients with hematological malignancies should 
consider the inclusion of  hematological malignancy-subtype-specific comorbid 
disease groups to improve prognostic prediction and treatment channeling.  
 Studies are needed to further investigate how clinicians can optimize patients with 
specific comorbid diseases to improve tolerance of intensive chemotherapy. 
 The treatment for hematological malignancies needs to be improved with use of more 
effective and at the same time less toxic agents. In this regard, the current 
development of a wide range of new therapeutic agents including targeted biological 
therapy for cancer including several hematological malignancies, holds promise for 
the future.  
 Risk factors for lymphoid malignancies are incompletely known, but do not appear to 
include surgical resection of lymphoid organs such as the appendix. 
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